Recipharm has announced it is joining the AMR Industry Alliance to contribute to exploring solutions to tackle growing concerns around antimicrobial resistance (AMR).
The AMR Industry Alliance is one of the largest coalitions set up to provide sustainable solutions to curb AMR. With over 100 members, including biotechnology, diagnostics, generics and pharmaceutical research organizations and associations, the alliance facilitates collaboration and informs external stakeholders about new developments in the field of AMR.
“AMR is currently one of the most serious health concerns worldwide. At Recipharm, we manufacture antibiotics in Sweden, Italy and India so it’s important that we get involved in developing solutions to combat AMR,” Erik Haeffler, VP of Manufacturing Services and Head of Sustainability at Recipharm said. “Joining the AMR Industry Alliance was the next natural step for us to take our work on AMR to the next level and allow us to engage with other stakeholders on the subject.”
“We welcome Recipharm as a new member of the alliance. In recent years we’ve seen more and more companies recognizing and addressing AMR and we’re delighted to see a leading CDMO like Recipharm committing to the objectives of the AMR Industry Alliance, including minimizing antibiotic emissions from the manufacturing supply chain,” Steve Brooks, Chair of the Manufacturing Working Group at the AMR Industry Alliance said.
AMR is recognized as a serious industry concern. The WHO, G7, G20 and many world leaders have acknowledged the growing dangers AMR presents and have called for concerted action from all relevant parties to work on solutions and their implementation.